At Blueprint Medicines, we work together toward one common goal: to develop breakthrough precision medicines that allow patients to live longer, healthier lives.
A team within Blueprint Medicines' global Medical Affairs organization is collaborating with research partners to use ‘real-world’ evidence from numerous sources to help providers more quickly identify and diagnose patients with systemic mastocytosis.
Our world-leading expertise in protein kinases, which are proven drivers of disease, powers the relentless development of transformational medicines. We believe our progress in the clinic reflects the power of our platform to rapidly and reproducibly pursue highly selective kinase medicines against diverse, difficult-to-drug targets.
Read more about our scientific platform
In addition to multiple research programs, we are currently advancing investigational medicines in clinical development for a broad range of genomically defined cancers and rare diseases.
View our clinical and research-stage pipeline Read more about our investigational medicines
Patients are at the center of Blueprint Medicines’ mission to discover, develop and deliver innovative medicines that address significant medical needs. From conducting rigorous clinical trials and supporting medical research, to successfully registering our medicines with global health authorities and providing a robust U.S. patient support program for our approved medicines through YourBlueprint™, we aim to bring innovative treatments to the greatest number of patients who may benefit, as quickly and responsibly as possible.
Read about our ongoing clinical trials View our policy on early access Find out about our U.S. patient support program, YourBlueprint™ Learn how we support investigator sponsored trialsFor more information, contact our medical information department: medinfo@blueprintmedicines.com
“Our team is comprised of scientific pioneers with profound expertise in protein kinases and clinical experts in cancer and rare diseases. Together, we aim to rapidly design and develop transformative precision therapies for patients in need.”Becker Hewes, M.D., Chief Medical Officer
